New derivatives of indole for the treatment of cancer, viral infections and lung diseases

A method for treating a cancer in a subject in need thereof comprising administering an effective amount of a pharmaceutical composition comprising a compound of formula (I):

• wherein:
• X represents a nitrogen atom, a C—CN unit or a N+—O− unit;
• R1 and R1′ are such that one is H and the other represents a halogen or a (C1-C6)alkoxy group, optionally substituted by a carboxylic group or one —NR11R12 unit wherein R11 and R12 represent H, a (C1-C6)alkyl group, or R11 and R12 taken together form a 3- to 7-membered ring, optionally interrupted by one or several heteroatoms;
• R2 represents:
• a radical (C1-C6)alkoxy, (C3-C6)cycloalkoxy, aryloxy, heteroaryloxy, (C1-C6)alkyl-aryloxy, (C1-C6)alkyl-heteroaryloxy, said radicals being optionally substituted by at least one halogen, or a radical thio-(C1-C6)alkyl, thio-aryl, thio-heteroaryl, thio-(C1-C6)alkyl-aryl or thio-(C1-C6)-alkyl-heteroaryl, said radicals being optionally substituted by at least one halogen or by a (C1-C6)alkoxy group,
• a —NR4R5 unit, a O—(C1-C6)alkyl-NR4R5 unit or a S—(C1-C6)alkyl-NR4R5 unit wherein R4 and R5 represent H, a (C1-C6)alkyl group, or R4 and R5 taken together form a 3- to 7-membered ring, optionally interrupted by one or several heteroatoms, with the proviso that at least one among R4 and R5 is not H,
• a NHCOR6 unit wherein R6 represents (C1-C6)alkyl group,
• an aryl or heteroaryl group optionally substituted by at least one halogen, a trifluoromethyl group, or a (C1-C3)alkoxy group, or
• a halogen,
• with the proviso that if R1 or R1′ is a (C1-C3)alkoxy group, then R2 is not a halogen;
• and
• R3 represents a hydrogen, a (C1-C3)alkyl group, a (C1-C3)alkoxy group or a halogen, advantageously a fluorine;
• and the compounds of formula (I) as above defined, in which the nitrogen atom of the indole core is substituted by a group selected from the group consisting of a COR7 and a CO2R7 group, wherein R7 represents:
• a (C1-C6)alkyl group, optionally substituted by at least a hydroxy group, a (C1-C6)alkyloxy group, a (C1-C6)npolyalkyloxy group wherein n is 1<n<6, a phosphate or pyrophosphate group and salts or (C1-C3)alkyl ester thereof, a R8 group, a —NHCO2R8 unit, a COR8 group, or a CO2R8 group, wherein R8 is:
• a (C1-C6)alkyl group,
• an aryl, a (C1-C6)alkylaryl, or a heteroaryl,
• a —NR9R10 unit wherein R9 and R10 represent a hydrogen, a (C1-C6)alkyl group, or R9 and R1 taken together form a 3- to 7-membered ring, optionally interrupted by one or several heteroatoms, and optionally the ring being substituted by at least one (C1-C6)alkyl group;
• a NH—NR9R10 unit wherein R9 and R10 are as defined above;
• or
• a saturated heterocycle or a heteroaryl;
• or one of its pharmaceutically acceptable salts.